Understanding the Staging of Multiple Myeloma
Multiple myeloma is a type of blood cancer that forms in plasma cells located in the bone marrow. Plasma cells are a vital component of the immune system responsible for producing antibodies that help fight infection. In multiple myeloma, these plasma cells grow uncontrollably and accumulate in the bone marrow, crowding out healthy blood cells.
Importance of Staging Multiple Myeloma
Staging multiple myeloma is an important step in determining the right treatment approach. Staging provides information about where the cancerous plasma cells are located and if they have spread beyond the bone marrow to other parts of the body.
Doctors use test results from blood and urine tests, biopsies, and imaging scans to assign a stage. The stage indicates the extent of the disease and if it has advanced to later stages. Understanding the stage helps doctors predict prognosis and survival rates and choose optimal therapies for each patient.
International Staging System
The most widely used staging system for myeloma is the International Staging System (ISS). This simple, three-stage system relies on two blood test results:
- Serum beta-2 microglobulin level
- Serum albumin level
These protein levels in the blood help determine myeloma cell mass in the body and how aggressive it may be. The ISS stages multiple myeloma as:
- Stage 1: Relatively small amount of tumor cells, prognosis is better
- Stage 2: Moderate number of myeloma cells and moderately aggressive
- Stage 3: Large number of myeloma cells, more aggressive and worse prognosis
Durie-Salmon Staging System
Another staging system sometimes used is the Durie-Salmon staging system. This uses four criteria to categorize myeloma into one of three stages:
- Stage I - relatively small number of myeloma cells in the body
- Stage II - moderate number of myeloma cells
- Stage III - large number of myeloma cells widely spread throughout the body
The four criteria used to determine the stage are:
- Blood calcium levels
- Severity of bone lesions
- Hemoglobin levels
- Amount of abnormal monoclonal protein in blood or urine
Tests Used in Staging
Doctors rely on the results from several medical tests to determine the cancers stage and decide on the ideal treatment plan. Tests used may include:
Blood and Urine Tests
Blood and urine samples can reveal abnormal protein produced by myeloma cells. Blood counts provide information on bone marrow function and kidney tests assess for kidney damage, which can occur with multiple myeloma.
Bone Marrow Biopsy and Aspiration
Extracting bone marrow samples with a biopsy and aspiration allows for a detailed analysis of plasma cells. Abnormal cells can be identified and their quantities measured through microscopic examination.
Molecular Testing
Special molecular tests assess bone marrow cells for specific genetic abnormalities. This information helps determine prognosis and target specific treatments.
Imaging Tests
X-rays, CT scans, PET scans and MRIs produce detailed images that identify compromised bones and bone damage. These compromised sites can be regularly assessed to gauge treatment efficacy.
Multiple Myeloma Stages
Multiple myeloma originates in the bone marrow before advancing to the later stages. The stages include:
Stage 0 - Monoclonal Gammopathy of Undetermined Significance
Abnormal plasma cells producing excessive monoclonal protein are present but growth isn't large or widespread enough to confirm diagnosis of multiple myeloma.
Stage I - Smoldering Multiple Myeloma
Criteria for multiple myeloma are met but generally no symptoms or detectable end organ damage from plasma cell accumulation.
Stage II - Symptomatic Multiple Myeloma
Myeloma cells have expanded significantly with moderate to severe symptoms and organ damage such as anemia, kidney dysfunction and bone destruction.
Stage III - Progressive Multiple Myeloma
Rapidly advancing with increased number and spread of myeloma cells leading to severe deterioration of health and organ function.
Prognostic Factors
In addition to the assigned ISS stage, doctors analyze certain prognostic factors that may predict disease aggressiveness, guide treatment and help estimate survival outcomes.
Cytogenetic Abnormalities
Genetic testing can detect high risk abnormalities of chromosomes in myeloma cells that lead to poorer outcomes.
Depth of Response
The extent to which treatment can reduce the number of myeloma cells is a significant prognostic factor.
Overall Health Status
A patients age, kidney function results, and other coexisting illnesses influence ability to tolerate certain intensive treatments.
Gene Expression Profiling
Newer testing analyzing gene expression patterns of myeloma cells may reveal whether the disease has high or low risk for progression.
Staging Guides Treatment Decisions
Multiple myeloma staging provides crucial information to determine appropriate therapy based on malignancy of the disease and risk of progression. Patients and doctors can use the staging data not only to select and sequence treatments but also to help cope with the diagnosis from a mental health standpoint.
FAQs
What are the most common staging systems used for multiple myeloma?
The two most widely used staging systems are the International Staging System (ISS) and the Durie-Salmon staging system. The simple, three-stage ISS relies on two blood protein levels while Durie-Salmon uses four specific criteria to categorize myeloma into one of three stages.
What medical tests help determine the stage?
Blood and urine tests, bone marrow biopsies, molecular/genetic testing, and imaging exams like X-rays, CT scans MRI help diagnose myeloma and identify the stage based on extent of spread and cell quantities.
How does staging influence treatment approach?
Staging helps guide doctor’s decisions on selecting and sequencing treatments for myeloma patients. Early stage disease can begin with less intensive approaches while advanced disease requires aggressive regimens like stem cell transplants.
What are some of the prognostic factors analyzed?
In addition to the assigned stage, doctors analyze prognostic factors like genetic abnormalities, depth of response to treatment, overall health status and gene expression that help predict disease progression.
Can multiple myeloma staging change over time?
Yes, as multiple myeloma advances, the cancer can move into more advanced stages. Doctors use repeated testing and monitoring to detect stage changes so treatments plans can be adjusted accordingly.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Related Coverage
Breaking a bone often leads to temporarily high white blood cell count as your body fights infection during injury healing. Learn causes, concerns, and recovery timeline....
Learn about the different staging systems used for multiple myeloma cancer such as the ISS and Durie-Salmon stages. Understand how staging guides treatment decisions....
Facing CAR T-cell failure in multiple myeloma? Find actionable next steps, including new therapies and clinical trials....
Learn about common and serious Empliciti side effects, how to manage them, and what symptoms require medical attention....
Get help with Talvey cost assistance through savings programs, insurance tips, and financial support for multiple myeloma treatment....
A true multiple myeloma cure remains out of reach, but today’s therapies can achieve lasting remissions that feel like a cure....
Metastatic multiple myeloma spreads to bones and organs, causing pain, fatigue, and issues; learn symptoms, treatments, care....
Find out what Talvey side effects look like, how often they occur, and practical steps to manage common, mild and serious reactions....
Revlimid for multiple myeloma offers a three‑pronged approach to slow disease, boost immunity, and extend quality life....
Learn about the latest statistics and research on multiple myeloma prognosis and life expectancy. Long-term survivors and emerging treatments provide hope....